A study by researchers at the Karolinska Institute (Karolinska Institutet), University of Gothenburg and Umea University (Umeå universitet) has found that rituximab provides better clinical outcomes than fingolimod (Gilenya), in people with MS that have ceased natalizumab (Tysabri) treatment due to becoming JCV+.
Full summary available: http://www.mstranslate.com.au/rituximab ... dividuals/
Rituximab vs fingolimod in JCV+ individuals
-
MStranslate
- Family Member
- Posts: 49
- Joined: Sun Mar 20, 2016 6:15 pm
- Location: Melbourne, Australia
- Contact:
Rituximab vs fingolimod in JCV+ individuals
Brett Drummond
MS Researcher/Science Communicator/Co-Founder of MStranslate
www.mstranslate.com.au
Facebook: www.facebook.com/MStranslate
MS Researcher/Science Communicator/Co-Founder of MStranslate
www.mstranslate.com.au
Facebook: www.facebook.com/MStranslate
-
- Similar Topics
- Replies
- Views
- Last post